Drug intelligence / Profile preview

tetanus peptide melanoma vaccine

Development stage: Approved
Lead developer: University of Virginia
Modality: Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration: Intradermal, Subcutaneous

Overview

The tetanus peptide melanoma vaccine is a cancer vaccine consisting of peptides derived from melanoma-associated antigens combined with a modified T-cell epitope derived from tetanus toxoid. It is designed to stimulate both helper T lymphocytes (HTL) and cytotoxic T lymphocytes (CTL) to generate an immune response against melanoma. The vaccine is administered as a water-in-oil emulsion, typically with an adjuvant such as Montanide ISA-51 and GM-CSF to enhance immune response.

Targets

TCR-TT-MHCII (T cell receptor recognizing tetanus toxoid peptide-MHC class II complex)MHC II (Major histocompatibility complex class II receptor)

Beyond the preview

Go deeper on tetanus peptide melanoma vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on tetanus peptide melanoma vaccine.

Explore the full profile